Defeat Duchenne Canadian Conference 2021: Addressing Duchenne muscular dystrophy (DMD) Standards of Care in Canada
The Neuromuscular Disease Network for Canada (NMD4C) in partnership with Jesse’s Journey and Muscular Dystrophy Canada (MDC), is proud to announce the inaugural Defeat Duchenne Canadian Conference, the first national summit solely focused on Duchenne muscular dystrophy (DMD) for health care providers across Canada.
The theme for this year’s virtual event is DMD standards of care (SoC). This three-part conference will bring together subject matter experts from pediatric and adult care for a comprehensive overview of the Canadian adaptation to the international DMD care considerations published in 2018.
What: Defeat Duchenne Canadian Conference: Addressing DMD Standards of Care in Canada
Who should attend: Multidisciplinary health care professionals involved in the care of DMD patients.
Session 1 (of 3): The first session will focus on the following DMD topics:
• Endocrinology management and bone health
• Cardiac management
• Pulmonary management
Friday, June 18, and Saturday, June 19, 2021, from 11 a.m. – 2 p.m. EDT each day. The second and third sessions will take place in September and December – stay tuned for registration later in the year.
Where: Online (Whova + Zoom)
We hope you and your team will join Jesse’s Journey and our partners as we build the future for Duchenne muscular dystrophy in Canada through research and collaboration.
First session of the three-part virtual conference starts June 18 and 19, 2021. Learn more about the sessions and speakers, and register today: www.dmdcanadianconference.com
Read next...
NMD4C Receive Excellence in Service Delivery Award and Network Investigators Honored as part of Muscular Dystrophy Canada’s 2024 Dr David Green Awards
We are excited to share that the NMD4C has been awarded the Excellence in Service Delivery Award, one of the annual Dr David Green Awards presented by Muscular Dystrophy Canada.
NMD4C Launch Canadian Neuromuscular Clinical Trial Network
We are thrilled to announce the launch of a Canadian neuromuscular clinical trial network (CTN) as a part of our clinical research work.
Training Session for Physiotherapists and Occupational Therapists on Outcome Measures in Spinal muscular atrophy hosted by Quebec SMA Network
This past March 23, the Quebec SMA Network (Réseau québécois de l’amyotrophie spinale – RQAS) in collaboration with the NMD4C and Muscular Dystrophy Canada (MDC) hosted an interactive training session for French-speaking physiotherapists and occupational therapists on assessment measures and practices for Spinal muscular atrophy (SMA). This training gathered clinicians to train and discuss SMA standardized outcome measures and work through current problems/challenges, to improve how these measures often tied to drug reimbursement are conducted.
MDC Announce Recipients of 2024 Neuromuscular Clinical and Translational Research Grants
Muscular Dystrophy Canada (MDC) recently announced the recipients of its annual Neuromuscular Research Grants competition. Through these grants, MDC is investing $900,000 into clinical and translational research projects.
SMA Outcome Measures Training for Physiotherapists and Occupational Therapists
To support the development and training on validated NMD outcome measures we are pleased to provide opportunities for physiotherapists and occupational therapists to attend training sessions for outcome measures.
Congratulations to the 2024 NMD4C Early Career Awards Recipients
We are excited to announce the recipients of the 2024 NMD4C Early Career Awards! This is the second year of our annual award program, celebrating excellence and contribution to the neuromuscular field from early career investigators across both clinical and basic science streams.